# Patterns and predictors of symptoms, falls, and functioning across treatment and recovery in patients treated with neurotoxic chemotherapy for cancer

> **NIH NIH R01** · OREGON HEALTH & SCIENCE UNIVERSITY · 2021 · $631,988

## Abstract

Recent reports suggest that falls increase by 25%-50% in cancer patients and are linked to treatment-related
side effects, such as chemotherapy-induced peripheral neuropathy (CIPN), that alter mobility (gait and balance).
Falls and functional impairments in cancer patients remain largely unrecognized and under-treated, in part
because it is not yet known what level of symptoms impact mobility, the specific mobility deficits that increase
fall and disability risk, or which patients are most at risk. Our long-term objective is to prevent falls and disability
associated with cancer treatment by informing clinicians about which and when patients show increased risk for
falls and functional decline and informing rehabilitation providers about which mobility deficits to target. A critical
first step toward this objective is to characterize the natural trajectories of symptoms, functioning, and falls across
the in-treatment and recovery phases of cancer care. To achieve this goal, we will use detailed symptom tracking,
simple clinical tests, passive continuous monitoring of daily mobility and physical activity, and self-report falls
and disability collected before, during, and one year after treatment in 200 patients prescribed neurotoxic
chemotherapy for cancer. The Specific Aims of this study are: 1) to characterize trajectories of neuropathy
symptoms and functioning (objective mobility, physical activity, self-report functioning and disability) across
treatment and one year of recovery among persons receiving neurotoxic chemotherapy for cancer and 2)
Determine the simplest predictors of symptom and functioning trajectories to identify patients in whom different
treatment options should be considered and/or who would benefit from early and targeted rehabilitation
interventions. This study is innovative because it will be the first study to 1) reveal how cancer treatment could
lead to increased risk of falls and disability in survivorship, 2) measure changes in symptoms, mobility and falls
across a course of chemotherapy and into recovery, 3) employ continuous passive monitoring technologies as
sensitive and specific measures of mobility and activity changes during daily life; and, 4) apply a novel analytic
approach - growth mixture modeling (GMM) - to identify the distinct trajectories of changes in symptoms,
functioning and falls associated with neurotoxic chemotherapy. Collectively the knowledge gained from this study
can be used to identify which patients might benefit from early intervention via alterations in treatment plans
and/or referral to rehabilitation. Findings from this study could provide new information for oncology teams to
improve patient safety and enhance survivorship care plans for those receiving neurotoxic chemotherapies.
Currently, clinical practice guidelines focus on pharmacologic management of pain associated with CIPN, which
remains suboptimal, with little attention to prevention of falls and functional decline. This study c...

## Key facts

- **NIH application ID:** 10260394
- **Project number:** 5R01CA248059-02
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** KERRI M WINTERS-STONE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $631,988
- **Award type:** 5
- **Project period:** 2020-09-10 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260394

## Citation

> US National Institutes of Health, RePORTER application 10260394, Patterns and predictors of symptoms, falls, and functioning across treatment and recovery in patients treated with neurotoxic chemotherapy for cancer (5R01CA248059-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10260394. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*